Display options
Cite
Qin J, Kunda N, Qiao G, et al. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017;8(2):e2584doi: 10.1038/cddis.2016.473.
Qin, J., Kunda, N., Qiao, G., Calata, J. F., Pardiwala, K., Prabhakar, B. S., & Maker, A. V. (2017). Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell death & disease, 8(2), e2584. https://doi.org/10.1038/cddis.2016.473
Qin, Jianzhong, et al. "Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death." Cell death & disease vol. 8,2 (2017): e2584. doi: https://doi.org/10.1038/cddis.2016.473
Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017 Feb 02;8(2):e2584. doi: 10.1038/cddis.2016.473. PMID: 28151483; PMCID: PMC5386459.
Copy Download .nbib Format: NLM
Share it on

Cell Death Dis. 2017 Feb 02;8(2):e2584. doi: 10.1038/cddis.2016.473.

Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.

Cell death & disease

Jianzhong Qin, Nicholas Kunda, Guilin Qiao, Jed F Calata, Krunal Pardiwala, Bellur S Prabhakar, Ajay V Maker

Affiliations

  1. Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, USA.
  2. Creticos Cancer Center, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
  3. Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA.

PMID: 28151483 PMCID: PMC5386459 DOI: 10.1038/cddis.2016.473

Abstract

Immunotherapeutic approaches to manage patients with advanced gastrointestinal malignancies are desired; however, mechanisms to incite tumor-specific immune responses remain to be elucidated. Rose bengal (RB) is toxic at low concentrations to malignant cells and may induce damage-associated molecular patterns; therefore, we investigated its potential as an immunomodulator in colon cancer. Murine and human colon cancer lines were treated with RB (10% in saline/PV-10) for cell cycle, cell death, and apoptosis assays. Damage-associated molecular patterns were assessed with western blot, ELISA, and flow cytometry. In an immunocompetent murine model of colon cancer, we demonstrate that tumors regress upon RB treatment, and that RB induces cell death in colon cancer cells through G2/M growth arrest and predominantly necrosis. RB-treated colon cancer cells expressed distinct hallmarks of immunogenic cell death (ICD), including enhanced expression of calreticulin and heat-shock protein 90 on the cell surface, a decrease in intracellular ATP, and the release of HMGB1. To confirm the ICD phenotype, we vaccinated immunocompetent animals with syngeneic colon cancer cells treated with RB. RB-treated tumors served as a vaccine against subsequent challenge with the same CT26 colon cancer tumor cells, and vaccination with in vitro RB-treated cells resulted in slower tumor growth following inoculation with colon cancer cells, but not with syngeneic non-CT26 cancer cells, suggesting a specific antitumor immune response. In conclusion, RB serves as an inducer of ICD that contributes to enhanced specific antitumor immunity in colorectal cancer.

References

  1. Proc Soc Exp Biol Med. 1960 Aug-Sep;104:650-3 - PubMed
  2. N Engl J Med. 2005 Dec 22;353(25):2654-66 - PubMed
  3. Biofactors. 2013 Jul-Aug;39(4):355-67 - PubMed
  4. Biomedicine. 1979 Oct;30(4):211-5 - PubMed
  5. Ann Surg Oncol. 2005 Dec;12 (12 ):1005-16 - PubMed
  6. AMA Arch Ophthalmol. 1951 Apr;45(4):419-24 - PubMed
  7. J Immunotoxicol. 2014 Oct;11(4):367-75 - PubMed
  8. Ann Surg Oncol. 2015 Jul;22(7):2135-42 - PubMed
  9. Melanoma Res. 2008 Dec;18(6):405-11 - PubMed
  10. Mol Ther. 2011 Mar;19(3):620-6 - PubMed
  11. J Cardiovasc Pharmacol. 2001 Dec;38(6):900-8 - PubMed
  12. Methods. 2008 Mar;44(3):205-21 - PubMed
  13. Oncoimmunology. 2012 May 1;1(3):271-278 - PubMed
  14. Front Immunol. 2015 Nov 20;6:588 - PubMed
  15. J Clin Cell Immunol. 2015 Aug;6(4):null - PubMed
  16. Nat Med. 2007 Jan;13(1):54-61 - PubMed
  17. PLoS One. 2014 Aug 20;9(8):e105778 - PubMed
  18. Food Chem Toxicol. 2009 Apr;47(4):855-9 - PubMed
  19. J Surg Oncol. 2014 Mar;109(4):314-9 - PubMed
  20. J Clin Oncol. 2010 Jul 20;28(21):3485-90 - PubMed
  21. Ann Surg Oncol. 2013 Mar;20(3):946-55 - PubMed
  22. Cell Cycle. 2007 Aug 15;6(16):1962-5 - PubMed
  23. Cell Death Differ. 2014 Jan;21(1):79-91 - PubMed
  24. Methods. 2013 Jun 1;61(2):117-29 - PubMed
  25. Med J Aust. 1951 Nov 24;2(21):708-9 - PubMed
  26. Science. 2006 Sep 29;313(5795):1960-4 - PubMed
  27. Lasers Surg Med. 2003;32(2):101-10 - PubMed
  28. Annu Rev Immunol. 2013;31:51-72 - PubMed
  29. J Immunol. 2005 Dec 1;175(11):7746-54 - PubMed
  30. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  31. Cell Death Differ. 2014 Jan;21(1):26-38 - PubMed
  32. Nat Rev Immunol. 2009 May;9(5):353-63 - PubMed
  33. Can Med Assoc J. 1927 Jul;17(7):878-80 - PubMed
  34. Oncoimmunology. 2015 Aug 12;5(1):e1069937 - PubMed
  35. Arch Ophthalmol. 1976 Nov;94(11):1899-1902 - PubMed
  36. PLoS One. 2013 Jul 17;8(7):e68561 - PubMed
  37. J Transl Med. 2013 Mar 20;11:70 - PubMed
  38. Nat Rev Mol Cell Biol. 2012 Dec;13(12):780-8 - PubMed
  39. Cell Death Dis. 2013 Dec 12;4:e966 - PubMed
  40. Cancer Immunol Res. 2015 Apr;3(4):380-8 - PubMed
  41. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):99-107 - PubMed
  42. EMBO J. 2012 Mar 7;31(5):1062-79 - PubMed
  43. ANZ J Surg. 2013 Jan;83(1-2):93 - PubMed

Substances

MeSH terms

Publication Types

Grant support